The Southwest Oncology Group (SWOG) represents the primary clinical investigative effort of the section of hematology-oncology of the department of medicine at the University of Oklahoma Health Sciences Center (OUHSC). This effort results in the enrollment of a consistently high number of eligible, evaluable patients into cooperative, group-based clinical trials. SWOG protocols at the University of Oklahoma remain the main opportunity for Oklahoma residents to participate in clinical oncology trials. Patients are accrued via both the parent institutions and associated CGOPs which serve large Native American populations and rural Oklahomans; annual accrual approximates 50 patients at Oklahoma Memorial Hospital (OMH), 20 patients at the Veterans Administration Hospital (OKC-VAMC), 10 patients at Presbyterian Hospital, 5 patients at South Community Hospital, and 55 patients through CGOPs. The participating faculty includes medical oncologists, hematologists, radiation oncologists, surgical specialists, and pathologists. This proposal is a concerted effort to organize these subspecialists into an efficient institutional cooperative group that can substantially increase our contributions to SWOG. Patient accrual has been a noteworthy strength of the OUHSC SWOG contribution, and has been characterized by a 50% rise over the last three years. In an effort to increase participation in the scholarly activities of clinical trials, the University has devoted considerable resources to develop an active inpatient oncology ward and bone marrow transplant unit and to recruit several new faculty members who will have an immediate impact on patient accrual and concept development. Preliminary effort toward developing new therapeutic approaches have been focused in the areas of bone marrow transplantation, head and neck cancer, and urological cancer. The final aspect of this proposal involves exploitation of the University of Oklahoma basic research base. The strong institutional commitment necessary for this effort is exemplified by the considerable local financial support and the number of new faculty and support personnel since the last submission of this grant, and the extensive inter-disciplinary collaborations which have occurred because of these changes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA058686-01
Application #
3559026
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-05-24
Project End
1997-12-31
Budget Start
1993-05-24
Budget End
1993-12-31
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
Schools of Medicine
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Arnold, Susanne M; Moon, James; Williamson, Stephen K et al. (2011) Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs 29:352-9

Showing the most recent 10 out of 87 publications